The concept of brain-computer interfaces in the US stock market is being hyped, and Regencell Bioscience continues to rise over 20% in after-hours trading

The concept of brain-computer interfaces in the US stock market is being heavily hyped, with Regencell Bioscience's stock price soaring 283% on June 13th Eastern Time, reaching an all-time high and a market capitalization exceeding $29.6 billion, continuing to rise over 20% in after-hours trading. The company's next-generation neuroregulation chip has received FDA approval for clinical trials and will collaborate with the Mayo Clinic to research Parkinson's disease. Recent news in the brain-computer interface field has been frequent, increasing market enthusiasm, with McKinsey estimating that the global medical application market could reach $40 billion to $145 billion between 2030 and 2040